These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21709690)

  • 21. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
    Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.
    Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
    Briganti A; Karakiewicz PI; Chun FK; Suardi N; Gallina A; Abdollah F; Freschi M; Doglioni C; Rigatti P; Montorsi F
    Int J Urol; 2009 Aug; 16(8):676-81. PubMed ID: 19602006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity and prostate cancer: epidemiology and clinical implications.
    Buschemeyer WC; Freedland SJ
    Eur Urol; 2007 Aug; 52(2):331-43. PubMed ID: 17507151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
    Paranhos M; Antunes A; Andrade E; Freire G; Srougi M
    BJU Int; 2009 Oct; 104(8):1130-3. PubMed ID: 19426190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort.
    Rodriguez C; Freedland SJ; Deka A; Jacobs EJ; McCullough ML; Patel AV; Thun MJ; Calle EE
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):63-9. PubMed ID: 17179486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of obesity on overall and cancer specific survival in men with prostate cancer.
    Davies BJ; Smaldone MC; Sadetsky N; Dall'era M; Carroll PR
    J Urol; 2009 Jul; 182(1):112-7; discussion 117. PubMed ID: 19447437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?
    Abdollah F; Briganti A; Suardi N; Gallina A; Capitanio U; Salonia A; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):74-8. PubMed ID: 20956995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia.
    Fowke JH; Motley SS; Wills M; Cookson MS; Concepcion RS; Eckstein CW; Chang SS; Smith JA
    Cancer Causes Control; 2007 May; 18(4):375-84. PubMed ID: 17334811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy.
    Salonia A; Gallina A; Briganti A; Abdollah F; Suardi N; Capitanio U; Colombo R; Freschi M; Rigatti P; Montorsi F
    Cancer; 2011 Sep; 117(17):3953-62. PubMed ID: 21365624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
    Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity, adipokines, and prostate cancer in a prospective population-based study.
    Baillargeon J; Platz EA; Rose DP; Pollock BH; Ankerst DP; Haffner S; Higgins B; Lokshin A; Troyer D; Hernandez J; Lynch S; Leach RJ; Thompson IM
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1331-5. PubMed ID: 16835332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher body mass index increases the risk for biopsy-mediated detection of prostate cancer in Chinese men.
    Hu MB; Bai PD; Wu YS; Zhang LM; Xu H; Na R; Jiang HW; Ding Q
    PLoS One; 2015; 10(4):e0124668. PubMed ID: 25861033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.